开云app官网登录入口网页版-官方正版

#PEG#

56篇内容 | 1820人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1533524, encodeId=17b415335244e, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Front Immunol：PEG-IFN a-2a治疗期间HBeAg阳性患者浆细胞样树突状细胞功能分子表达与HBsAg丢失相关, objectType=article, longId=736354, objectId=8d4ce36354d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d4ce36354d3, replyNumber=0, likeNumber=153, createdTime=2022-08-21, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d4ce36354d3, moduleTitle=Front Immunol：PEG-IFN a-2a治疗期间HBeAg阳性患者浆细胞样树突状细胞功能分子表达与HBsAg丢失相关, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8d4ce36354d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533523, encodeId=89731533523f2, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, objectType=article, longId=730487, objectId=eb89e30487a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e30487a4, replyNumber=0, likeNumber=75, createdTime=2022-06-27, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e30487a4, moduleTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=eb89e30487a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533522, encodeId=26871533522ea, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=JAMA Oncol：Etirinotecan pegol vs 化疗治疗有脑转移的乳腺癌的预后, objectType=article, longId=727101, objectId=5187e27101bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5187e27101bb, replyNumber=0, likeNumber=69, createdTime=2022-05-18, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5187e27101bb, moduleTitle=JAMA Oncol：Etirinotecan pegol vs 化疗治疗有脑转移的乳腺癌的预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5187e27101bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533521, encodeId=2474153352122, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=J Immunother Cancer：Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌, objectType=article, longId=725499, objectId=bec0e25499db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec0e25499db, replyNumber=0, likeNumber=0, createdTime=2022-04-28, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec0e25499db, moduleTitle=J Immunother Cancer：Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bec0e25499db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533520, encodeId=a4a7153352010, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=美国FDA核准BESREMi® (Ropeginterferon α-2b), objectType=article, longId=220622, objectId=7e4422062262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4422062262, replyNumber=0, likeNumber=92, createdTime=2021-11-21, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4422062262, moduleTitle=美国FDA核准BESREMi® (Ropeginterferon α-2b), moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7e4422062262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533519, encodeId=406015335192a, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Aspaveli (pegcetacoplan) 治疗阵发性夜间血红蛋白尿症 (PNH)，已获得欧盟CHMP积极意见, objectType=article, longId=218729, objectId=4cd6218e291b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cd6218e291b, replyNumber=0, likeNumber=85, createdTime=2021-10-18, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cd6218e291b, moduleTitle=Aspaveli (pegcetacoplan) 治疗阵发性夜间血红蛋白尿症 (PNH)，已获得欧盟CHMP积极意见, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4cd6218e291b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533518, encodeId=be871533518e6, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=NEJM：Efpeglenatide治疗2型糖尿病的心血管和肾脏结局, objectType=article, longId=216606, objectId=acd4216606b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acd4216606b6, replyNumber=0, likeNumber=71, createdTime=2021-09-03, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acd4216606b6, moduleTitle=NEJM：Efpeglenatide治疗2型糖尿病的心血管和肾脏结局, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=acd4216606b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533517, encodeId=0748153351ec9, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Urol Int：miR-155-5p通过靶向PEG3促进透明细胞肾细胞癌的细胞增殖和迁移, objectType=article, longId=214394, objectId=d7d421439443, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7d421439443, replyNumber=0, likeNumber=81, createdTime=2021-07-20, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7d421439443, moduleTitle=Urol Int：miR-155-5p通过靶向PEG3促进透明细胞肾细胞癌的细胞增殖和迁移, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d7d421439443)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533516, encodeId=5c061533516aa, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, objectType=article, longId=214261, objectId=08ac21426112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08ac21426112, replyNumber=0, likeNumber=54, createdTime=2021-07-17, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08ac21426112, moduleTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=08ac21426112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533515, encodeId=c199153351500, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=J Clin Oncol：Pegaspargase和Calaspargase Pegol治疗儿童ALL的疗效和毒性, objectType=article, longId=214106, objectId=eb67214106de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb67214106de, replyNumber=0, likeNumber=75, createdTime=2021-07-14, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb67214106de, moduleTitle=J Clin Oncol：Pegaspargase和Calaspargase Pegol治疗儿童ALL的疗效和毒性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=eb67214106de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533514, encodeId=61261533514d0, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用, objectType=article, longId=213591, objectId=78a9213591c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78a9213591c8, replyNumber=0, likeNumber=94, createdTime=2021-07-02, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78a9213591c8, moduleTitle=NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=78a9213591c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533513, encodeId=c8041533513b0, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=NEJM：Pegcetacoplan对于阵发性睡眠性血红蛋白尿的治疗效果优于Eculizumab, objectType=article, longId=208673, objectId=25e82086e3fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25e82086e3fe, replyNumber=0, likeNumber=82, createdTime=2021-03-20, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25e82086e3fe, moduleTitle=NEJM：Pegcetacoplan对于阵发性睡眠性血红蛋白尿的治疗效果优于Eculizumab, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=25e82086e3fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533512, encodeId=bd93153351262, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Br J Cancer：ADI-PEG20联合顺铂治疗转移性恶性实体瘤, objectType=article, longId=207933, objectId=550020e93315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=550020e93315, replyNumber=0, likeNumber=69, createdTime=2021-03-07, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=550020e93315, moduleTitle=Br J Cancer：ADI-PEG20联合顺铂治疗转移性恶性实体瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=550020e93315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533511, encodeId=101915335118f, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, objectType=article, longId=207010, objectId=0c9920e0107e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c9920e0107e, replyNumber=0, likeNumber=72, createdTime=2021-02-11, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c9920e0107e, moduleTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0c9920e0107e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533510, encodeId=62421533510ee, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期, objectType=article, longId=204053, objectId=0bbe204053d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bbe204053d5, replyNumber=0, likeNumber=85, createdTime=2020-12-04, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bbe204053d5, moduleTitle=FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0bbe204053d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533509, encodeId=412315335090c, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Blood：重组FVIII药物Rurioctocog alfa pegol预防性治疗A型血友病, objectType=article, longId=203528, objectId=9b0d20352851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b0d20352851, replyNumber=0, likeNumber=66, createdTime=2020-11-20, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b0d20352851, moduleTitle=Blood：重组FVIII药物Rurioctocog alfa pegol预防性治疗A型血友病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9b0d20352851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533508, encodeId=19181533508e5, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=DCR: PEG10基因的差异表达有助于早期发病与晚期发作性大肠癌的疾病侵略性, objectType=article, longId=203223, objectId=8c5920322388, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c5920322388, replyNumber=0, likeNumber=73, createdTime=2020-11-11, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c5920322388, moduleTitle=DCR: PEG10基因的差异表达有助于早期发病与晚期发作性大肠癌的疾病侵略性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8c5920322388)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533507, encodeId=301e153350e57, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Pharmaceutics：壳聚糖水凝胶掺杂PEG-PLA纳米颗粒来局部递送miRNA-146a和治疗变应性鼻炎, objectType=article, longId=202457, objectId=68f020245ef3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68f020245ef3, replyNumber=0, likeNumber=78, createdTime=2020-10-26, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68f020245ef3, moduleTitle=Pharmaceutics：壳聚糖水凝胶掺杂PEG-PLA纳米颗粒来局部递送miRNA-146a和治疗变应性鼻炎, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=68f020245ef3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533506, encodeId=bda21533506ef, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著, objectType=article, longId=195820, objectId=4ad419582055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ad419582055, replyNumber=0, likeNumber=58, createdTime=2020-06-15, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ad419582055, moduleTitle=EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4ad419582055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533505, encodeId=4ac11533505ac, content=<a href='/topic/show?id=e59c1400060' target=_blank style='color:#2F92EE;'>#PEG#</a>, objectTitle=Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！, objectType=article, longId=187425, objectId=b82918e4252e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b82918e4252e, replyNumber=0, likeNumber=53, createdTime=2020-02-06, rootId=0, userName=wleon8899, userId=bbc812457783, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b82918e4252e, moduleTitle=Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b82918e4252e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

PEG

2020-05-29

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Front Immunol：PEG-IFN a-2a治疗期间HBeAg阳性患者浆细胞样树突状细胞功能分子表达与HBsAg丢失相关

2022-08-21

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？

2022-06-27

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

JAMA Oncol：Etirinotecan pegol vs 化疗治疗有脑转移的乳腺癌的预后

2022-05-18

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

J Immunother Cancer：Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌

2022-04-28

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

美国FDA核准BESREMi® (Ropeginterferon α-2b)

2021-11-21

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Aspaveli (pegcetacoplan) 治疗阵发性夜间血红蛋白尿症 (PNH)，已获得欧盟CHMP积极意见

2021-10-18

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

NEJM：Efpeglenatide治疗2型糖尿病的心血管和肾脏结局

2021-09-03

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Urol Int：miR-155-5p通过靶向PEG3促进透明细胞肾细胞癌的细胞增殖和迁移

2021-07-20

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤

2021-07-17

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

J Clin Oncol：Pegaspargase和Calaspargase Pegol治疗儿童ALL的疗效和毒性

2021-07-14

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用

2021-07-02

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

NEJM：Pegcetacoplan对于阵发性睡眠性血红蛋白尿的治疗效果优于Eculizumab

2021-03-20

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Br J Cancer：ADI-PEG20联合顺铂治疗转移性恶性实体瘤

2021-03-07

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效

2021-02-11

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期

2020-12-04

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Blood：重组FVIII药物Rurioctocog alfa pegol预防性治疗A型血友病

2020-11-20

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

DCR: PEG10基因的差异表达有助于早期发病与晚期发作性大肠癌的疾病侵略性

2020-11-11

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Pharmaceutics：壳聚糖水凝胶掺杂PEG-PLA纳米颗粒来局部递送miRNA-146a和治疗变应性鼻炎

2020-10-26

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

EHA 2020：III期头对头研究证实C3补体抑制剂pegcetacoplan治疗阵发性夜间血红蛋白尿疗效显著

2020-06-15

wleon8899 (审核中...)

前往app查看评论内容

#PEG#

Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！

2020-02-06

科室
- - 订阅+
  - 更多科室
工具
服务